|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Keeshia Muhammad, Teva Specialty Pharmaceuticals

Keeshia Muhammad

Keeshia Muhammad

Executive Director, Marketing, Teva Specialty Pharmaceuticals

MAKES PHARMA A BETTER PLACE: The Healthcare Businesswomen's Association

REWARD: Standing ovations for marketing teams from the sales force

Keeshia Muhammad says much of what you need to know about co-promotion you learned in kindergarten. "It's about collaborating with people, with the foundation of integrity, trust, and respect. Hidden agendas ultimately tarnish relationships as you start to build a team."

Keeshia Muhammad

And she should know. Muhammad worked on the Merck/Schering-Plough joint venture for Zetia and Vytorin, maintained Altana's voice in its COPD hopeful PDE-4 inhibitor partnership with Pfizer, and managed Altana's co-promotion of Alvesco with Sanofi-Aventis. While she may have played nice in the past, Muhammad is showing an edge in her new role. Under her leadership, Teva's flagship asthma brand ProAir HFA has nearly doubled its market share to 60 percent. So how does she do it? "I bring passion and energy to the table," she says. "I always have people asking me, 'Can I have a dose of that?'"

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.